ArticleEndocrine connections2019
Metabolic effects of dopamine agonists in patients with prolactinomas: a systematic review and meta-analysis.
Article in Endocrine connections, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 27 citations in OpenAlex.
- Serum FGF-23 and α-Klotho Levels in Prolactinoma and Non-Tumoral Hyperprolactinemia: An Exploratory Cross-Sectional Comparative Study.Diagnostics (Basel, Switzerland) · 2026Article
- Very low-density lipoprotein and the human health.World journal of experimental medicine · 2026Review
- Bromocriptine in type 2 diabetes: a promising alternative, a systematic review and meta-analysis.Cardiovascular diabetology. Endocrinology reports · 2025Article
- Abnormally Increased Prolactin Levels in Women with Polycystic Ovarian Syndrome Are Associated with Risk of Obesity, Insulin Resistance and Prediabetes.International journal of molecular sciences · 2025Article
- Smoking, Obesity, and Post-Cessation Weight Gain: Neurobiological Intersection and Treatment Recommendations.Journal of multidisciplinary healthcare · 2025Review
- Drug induced hypoprolactinemia.Reviews in endocrine & metabolic disorders · 2024Review
- The homeo-FIT-prolactin hypothesis: the role of prolactin in metabolic homeostasis - association or causality?Reviews in endocrine & metabolic disorders · 2024Review
- Characteristics and outcomes of men with erectile dysfunction as the presenting symptom due to a lactotroph adenoma.Acta neurochirurgica · 2024Article
- Commentary: Clinical characteristics of male prolactinoma patients mainly presenting with severe obesity and the metabolic response to dopamine agonist therapy.Frontiers in endocrinology · 2024Article
- Dopamine 2 agonists for the management of type 2 diabetes: a systematic review and meta-analysis.Journal of diabetes and metabolic disorders · 2023Review
- Review
- Article
- Editorial: The metabolic effect of prolactin.Frontiers in endocrinology · 2023Article
- Emerging Evidence of Pathological Roles of Very-Low-Density Lipoprotein (VLDL).International journal of molecular sciences · 2022Review
- The interplay between prolactin and cardiovascular disease.Frontiers in endocrinology · 2022Review
- Change in Insulin Sensitivity and Lipid Profile After Dopamine Agonist Therapy in Patients With Prolactinoma.Cureus · 2021Article
- Impact of primary medical or surgical therapy on prolactinoma patients' BMI and metabolic profile over the long-term.Journal of clinical & translational endocrinology · 2021Article
- The Effects ofFrontiers in pharmacology · 2021Article
- Metabolic Abnormalities, Inflammatory Markers and Endothelial Dysfunction in Hyperprolactinemia due to Prolactinoma before and after Normalization of Serum Prolactin: A Prospective Case Control Study.Indian journal of endocrinology and metabolismArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesRecent large cohort studies suggest an association between high plasma prolactin and cardiovascular mortality. The objective of this systematic review was to systematically assess the effect of reducing prolactin with dopamine agonist on established cardiovascular risk factors in patients with prolactinomas.
designBibliographical search was done until February 2019 searching the following databases: PubMed, EMBASE, WHO and LILAC. Eligible studies had to include participants with verified prolactinomas where metabolic variables were assessed before and after at least 2 weeks treatment with dopamine agonists.
methodsBaseline data and outcomes were independently collected by two investigators. The study was registered with PROSPERO (registration number CRD42016046525).
resultsFourteen observational studies enrolling 387 participants were included. The pooled standardized mean difference of the primary outcome revealed a reduction of BMI and weight of -0.21 (95% CI -0.37 to -0.05; P = 0.01; I2 = 71%), after treatment. Subgroup analysis suggested that the reduction of weight was primarily driven by studies with high prolactin levels at baseline (P = 0.04). Secondary outcomes suggested a small decrease in waist circumference, a small-to-moderate decrease in triglycerides, fasting glucose levels, HOMA-IR, HbA1c and hsCRP, and a moderate decrease in LDL, total cholesterol and insulin.
conclusionThis systematic review suggests a reduction of weight as well as an improved lipid profile and glucose tolerance after treatment with dopamine agonist in patients with prolactinomas. These data are based on low-quality evidence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.